Evidence map›Paper›PMID 30622934›Full record

ArticleFrontiers in cellular and infection microbiology2018

Jung-Hyun Na, Tae Hee Lee, Soo-Bong Park, Min-Kyu Kim, Bo-Gyeong Jeong, Kyung Min Chung, Sun-Shin Cha

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Identification of Potential Drug Targets inPathogens (Basel, Switzerland) · 2020
    Article
  6. Recent advances in the development of β-lactamase inhibitors.Journal of microbiology (Seoul, Korea) · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Jung-Hyun NaDepartment of Chemistry and Nanoscience, Ewha Womans University, Seoul, South Korea.
Tae Hee LeeDepartment of Microbiology and Immunology, Chonbuk National University Medical School, Jeonju, South Korea.
Soo-Bong ParkDepartment of Chemistry and Nanoscience, Ewha Womans University, Seoul, South Korea.
Min-Kyu KimBiotechnology Research Division, Korea Atomic Energy Research Institute, Jeongeup, South Korea.
Bo-Gyeong JeongDepartment of Chemistry and Nanoscience, Ewha Womans University, Seoul, South Korea.
Kyung Min ChungDepartment of Microbiology and Immunology, Chonbuk National University Medical School, Jeonju, South Korea.
Sun-Shin ChaDepartment of Chemistry and Nanoscience, Ewha Womans University, Seoul, South Korea.
Ewha Womans University · KRJeonbuk National University · KRKorea University of Science and Technology · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

β-Lactamase-mediated resistance to β-lactam antibiotics has been significantly threatening the efficacy of these clinically important antibacterial drugs. Although some β-lactamase inhibitors are prescribed in combination with β-lactam antibiotics to overcome this resistance, the emergence of enzymes resistant to current inhibitors necessitates the development of novel β-lactamase inhibitors. In this study, we evaluated the inhibitory effect of dinucleotides on an extended-spectrum class C β-lactamase, AmpC BER. Of the dinucleotides tested, NADPH, a cellular metabolite, decreased the nitrocefin-hydrolyzing activity of the enzyme with a

Indexed as

AnimalsAnti-Bacterial AgentsBacterial Proteinsbeta-LactamasesCeftazidimeCephalosporinsDisease Models, AnimalDrug Therapy, CombinationEnzyme InhibitorsEscherichia coliEscherichia coli InfectionsHydrolysisIndicators and ReagentsMiceMicrobial Sensitivity TestsNADPAmpC beta-lactamasesAnti-Bacterial AgentsBacterial Proteinsbeta-LactamasesCeftazidimeCephalosporinsEnzyme InhibitorsIndicators and ReagentsNADPnitrocefinAmpC BERantimicrobial resistanceclass C β-lactamasemouse infection modelNADPHβ-lactamase inhibitors

Identifiers

PMID30622934
PMCPMC6308799
OpenAlexW2906607158

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.